Cargando…
Use of apatinib combined with pemetrexed for advanced ovarian cancer: A case report
INTRODUCTION: Ovarian cancer is the most deadly gynecologic cancer, and the therapy is very difficult. Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2. At present, there are few studies or case reports on apatinib treatment for patients with ovar...
Autores principales: | Sun, Huiting, Xiao, Min, Liu, Sufen, Shi, Ruxia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076125/ https://www.ncbi.nlm.nih.gov/pubmed/29979376 http://dx.doi.org/10.1097/MD.0000000000011036 |
Ejemplares similares
-
The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
por: Zhou, Ling, et al.
Publicado: (2023) -
Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report
por: Deng, Linghui, et al.
Publicado: (2017) -
A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019) -
Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report
por: Zhang, Mingzi, et al.
Publicado: (2017) -
Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
por: Wang, Zhongyu, et al.
Publicado: (2021)